New insights into paroxysmal nocturnal hemoglobinuria

Current Opinion in Hematology

Volumn 8, Issue 2, 2001, Pages 61-67

  Rosse, Wendell F ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; GLYCOSYLPHOSPHATIDYLINOSITOL; PROTEIN PIGA; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW DEPRESSION; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCOAGULABILITY; INTRAVASCULAR HEMOLYSIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RELIABILITY; SOMATIC MUTATION;

ANIMALS; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MEMBRANE PROTEINS; MUTATION;

EID: 0035093144     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-200103000-00001     Document Type: Article

References (64)

1. Paroxysmal nocturnal hemoglobinuria as a molecular disease
2. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria
3. GPI-anchor synthesis in mammalian cells: Genes, their products, and a deficiency
4. Transfusion-related acute lung injury due to granulocyte-agglutinating antibody in a patient with paroxysmal nocturnal hemoglobinuria
5. Acute reversible renal failure in a patient with paroxysmal nocturnal hemoglobinuria
6. The kidneys in paroxysmal nocturnal hemoglobinuria
7. Paroxysmal nocturnal haemoglobinuria: Long term follow-up and prognostic factors
8. Natural history of paroxysmal nocturnal hemoglobinuria
9. Fetomaternal outcomes of pregnancy in paroxysmal nocturnal hemoglobinuria
10. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria
11. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia
12. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
13. Paroxysmal nocturnal haemoglobinuria: Variation in clinical severity and association with bone marrow hypoplasia
14. High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia-A possible role of high endogenous IL-2 in their suppression
15. Paroxysmal nocturnal hemoglobinuria cells in patients with bone marrow failure syndromes
16. Leukemia arising out of paroxysmal nocturnal hemoglobinuria
17. Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: Certain immunologic aspects of the hemolytic mechanism with special reference to serum complement
18. The "sugar water" test for paroxysmal nocturnal hemoglobinuria
19. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody
20. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor
21. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria
22. The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria
23. Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria
24. Improved detection and characterization of paroxysmal nocturnal hemoglobinuria using flouorescent aerolysin
25. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals
26. Genomio organization of the X-linked gene (PIG-A) that is mutated in paroxysmal nocturnal haemoglobinuria and of a related autosomal pseudogene mapped to 12q21
27. Paroxysmal nocturnal hemoglobinuria: Molecular pathogenesis and molecular therapeutic approaches
28. A patient with paroxysmal nocturnal hemoglobinuria bearing four independent PIG-A mutant clones
29. Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria
30. The structure and biosynthesis of glycosyl-phosphatidylinositol protein anchors
31. Biosynthesis of glycosylphosphatidylinositols in mammals and unicellular microbes
32. Glycosylphosphatidylinositolanchor-deficient mice: Implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria
33. Studies on phosphatidylinositol phospholipase (phospholipase C type) of Bacillus cereus. I. Purification, properties, and phosphatase releasing activity
34. Glycosylphosphatidylinositol-phospholipase D: A tool for glycosylphosphatidylinositol structural analysis
35. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes
36. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium
37. Correction of the PNH defect by GPI-anchored protein transfer
38. Role of decay-accelerating factor in regulating complement activation on the erythrooyte surface as revealed by gene targeting
39. Phenotypic and functional analysis of lymphocytes in paroxysmal nocturnal hemoglobinuria
40. Defective TCR signaling events in glycosylphosphatidylinositol-deficient T cells derived from paroxysmal nocturnal hemoglobinuria patients
41. Analysis of T cells in paroxysmal nocturnal hemoglobinuria provides direct evidence that T-cell production declines with age
42. Lymphocyte subset analysis and glycosylphosphatidylinositol phenotype in patients with paroxysmal nocturnal hemoglobinuria
43. Antibody cross-linking of the glycosylphosphatidylinositor-linked protein CD59 on hematopoietic cells induces signaling pathways resembling activation by complement
44. Endotoxin binding and elimination by monocytes: Secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria
45. Somatic mutation and clonal selection in the pathogenesis and in the control of paroxysmal nocturnal hemoglobinuria
46. Hematopoietic progenitor cells in the blood and bone marrow in various hematologic disorders
47. Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria
48. Paroxysmal nocturnal hemoglobinuria associated with in vitro inhibition of erythropoiesis by bone marrow T lymphocytes
49. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria
50. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria
51. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria
52. X inactivation and somatic cell selection rescue female mice carrying a Piga-null mutation
53. Thrombolytic therapy for inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria
54. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria
55. High-dose recombinant human erythropoietin and low-dose corticosteroids for treatment of anemia in paroxysmal nocturnal hemoglobinuria
56. Recombinant human erythropoietin for long-term therapy of anemia in paroxysmal nocturnal hemoglobinuria
57. Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia
58. Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation
59. Bone marrow transplantation for paroxysmal nocturnal hemoglobinuria
60. Aplasfic anemia and paroxysmal nocturnal hemoglobinuria: Search for a pathogenetic link
61. Identical twin marrow transplantation for venous thrombosis in paroxysmal nocturnal hemoglobinuria: Long-term complete remission as assessed by flow cytometry
62. Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria
63. New somatic mutation in the PIG-A gene emerges at relapse of paroxysmal nocturnal hemoglobinuria
64. Efficient retrovirus-mediated PIG-A gene transfer and stable restoration of GPI-anchored protein expression in cells with the PNH phenotype